|
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Canadian Institutes of Health Research Membrane Protein Research Group (F.V., J.Z., R.T.R., J.D.Y, C.E.C.), Departments of Oncology (F.V., J.Z., R.T.R., C.E.C.) and Physiology (J.D.Y.), University of Alberta and the Cross Cancer Institute (F.V., J.Z., R.T.R., C.E.C.), Edmonton, Alberta, Canada; and the School of Biochemistry and Microbiology, University of Leeds, Leeds, United Kingdom (S.A.B.)
Abstract
Human equilibrative nucleoside transporters 1 and 2 (hENT1 and hENT2) differ functionally in that hENT2 generally displays lower affinity for its nucleoside permeants and is less sensitive to inhibition by the coronary vasodilators dilazep and dipyridamole. In previous work, we demonstrated that mutation of residues 33 (Met versus Ile) of hENT1 and hENT2 altered sensitivity to dilazep and dipyridamole and that the hENT2 mutant (I33M) displayed a Km value for uridine that was lower than that of hENT2 and similar to that of hENT1 (J Biol Chem 277:395-401, 2002). In this study, we report results of an in-depth investigation of the role of residue 33 in hENT2. We found that hENT2-I33M displayed decreased Km values for both pyrimidine and purine nucleosides and increased Vmax values for purine nucleosides. Cys or Ser at position 33 had similar effects on the kinetic parameters of hENT2 as Met, indicating that hydrophobic (Met and Cys) or hydrogen-bonding energy (Ser) contributed to permeant binding by these residues. hENT2-I33M and I33C displayed increased sensitivities to dipyridamole compared with wild-type hENT2, hENT2-I33A, and hENT2-I33S, suggesting interaction of the sulfur atom of Met and Cys with aromatic moieties on dipyridamole. hENT2-I33C was inhibited by the membrane-impermeant sulfhydryl reactive reagent p-chloromercuribenzyl sulfonate, and uridine, adenosine, and dipyridamole protected against inhibition. Our results indicated that residue 33 resides in an extracellular domain as predicted by the current hENT2 topology model and suggested that it is a functionally important component of both the permeant and dipyridamole binding sites.
Address correspondence to: Dr. Carol E. Cass, Department of Oncology, Cross Cancer Institute, 11560 University Ave., T6G 1Z2, Edmonton, AB T6G 1Z2, Canada. E-mail: carol.cass{at}cancerboard.ab.ca
This article has been cited by other articles:
![]() |
K. R. Robillard, D. B.J. Bone, J. S. Park, and J. R. Hammond Characterization of mENT1{Delta}11, a Novel Alternative Splice Variant of the Mouse Equilibrative Nucleoside Transporter 1 Mol. Pharmacol., July 1, 2008; 74(1): 264 - 273. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Visser, L. Sun, V. Damaraju, T. Tackaberry, Y. Peng, M. J. Robins, S. A. Baldwin, J. D. Young, and C. E. Cass Residues 334 and 338 in Transmembrane Segment 8 of Human Equilibrative Nucleoside Transporter 1 Are Important Determinants of Inhibitor Sensitivity, Protein Folding, and Catalytic Turnover J. Biol. Chem., May 11, 2007; 282(19): 14148 - 14157. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Zhang, K. M. Smith, T. Tackaberry, X. Sun, P. Carpenter, M. D. Slugoski, M. J. Robins, L. P. C. Nielsen, I. Nowak, S. A. Baldwin, et al. Characterization of the Transport Mechanism and Permeant Binding Profile of the Uridine Permease Fui1p of Saccharomyces cerevisiae J. Biol. Chem., September 22, 2006; 281(38): 28210 - 28221. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Zhang, K. M. Smith, T. Tackaberry, F. Visser, M. J. Robins, L. P. C. Nielsen, I. Nowak, E. Karpinski, S. A. Baldwin, J. D. Young, et al. Uridine Binding and Transportability Determinants of Human Concentrative Nucleoside Transporters Mol. Pharmacol., September 1, 2005; 68(3): 830 - 839. [Abstract] [Full Text] [PDF] |
||||